Vaccine

mRNA COVID-19 vaccines produce lasting virus-specific antibodies and T cells in lung transplant patients who had COVID-19 before

Updated

Abstract

At a median of 184 days after prior SARS-CoV-2 infection, lung transplant recipients were vaccinated twice with the mRNA-1273 COVID-19 vaccine.

  • Most lung transplant recipients with prior infection had detectable spike-specific antibodies and T cells before vaccination.
  • Spike-specific antibody levels increased significantly after the first vaccination, with an additional increase after the second vaccination.
  • Nucleocapsid-specific antibodies decreased during the study period, suggesting no further breakthrough infections occurred.
  • An increase in T cells producing IFN-γ was observed after the first vaccination, but no further boost was detected after the second vaccination.
  • Antibody levels and virus-specific T cell responses remained significantly higher than pre-vaccination levels at 6 months post-vaccination.
  • Neutralizing antibodies were detected against the ancestral strain and showed some cross-reactivity with the Omicron BA.5 variant.

Simplified

Full Text

Full text is available at the source.

Funding

Competing interests

Declaration of competing interest The authors declare the following financial support was received for the research. Coretta Van Leer Buter reports financial support was provided by the Netherlands Organization for Health Research and Development (ZonMW), projectnumber: 10430072010003. Siqi Liu reports financial support was provided by Chinese Scholarship Council (CSC NO.201909110111). All authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.
PubMed

What Lands in Your Inbox Each Week:

  • 📚7 fresh studies
  • 📝plain-language summaries
  • ✅direct links to original studies
  • 🏅top journal indicators
  • 📅weekly delivery
  • 🧘‍♂️always free